Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

University City-based life sciences startup Fore Biotherapeutics managed to bring in $38 million in new funding during a ...

Bicara Therapeutics presented data from an ongoing, 28-patient trial of its drug showing median overall survival of over 21 ...

The IDMO Smart Factory initiative has the potential to help advance the development and approval of CAR-T therapeutics in ...

Biogen and City Therapeutics have announced a partnership worth over $1bn to develop new RNAi therapies. The collaboration ...

Biogen partners with City Therapeutics to develop select novel RNAi-based therapies: Cambridge, Massachusetts Thursday, May 29, 2025, 10:00 Hrs [IST] Biogen Inc, a leading biotech ...

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Nearly two years in with Zurzuvae, Biogen tackles an ‘all of the above market’ to find patients and battle stigma in ...

A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments.

Healthcare companies rose as traders mulled the latest tariff headlines amid higher-than-expected May consumer confidence. Shares of Hologic advanced 15% after the Financial Times reported the company ...